查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197439

活細胞封裝市場COVID-19 的增長、趨勢、影響和預測2023-2028

Live Cell Encapsulation Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，活細胞封裝市場預計將以近 3.2% 的複合年增長率增長。

活細胞封裝市場受到 COVID-19 的巨大影響。 然而，各種 COVID-19 疫苗都是 RNA 封裝的。 例如，根據 2021 年 10 月在病毒研究雜誌上發表的題為“COVID-19 疫苗”、“COVID-19 疫苗：綜合狀況報告”的研究，發現 1273 mRNA (Moderna TX, Inc. SARS-full -length，一種疫苗，其中編碼 CoV-2 融合前穩定刺突蛋白的合成 mRNA 被包裹在脂質納米顆粒 (LNP) 中。Codagenix 正在與印度血清研究所合作開發減毒活病毒疫苗，活細胞封裝市場已受到 COVID-19 的影響。

促進活細胞封裝市場增長的主要因素是為產品開發提供資金的公共和私人投資不斷增加。 例如，2021 年 7 月，在新加坡和泰國開展業務的全球性公司 Austrianova 使用基於硫酸纖維素的材料生產活體哺乳動物 (Cell-in-a-Box) 和細菌 (Bac-in-a-Box) 我們是開發新的和獨特的細胞封裝技術。 由於 Realtek 投資該基金作為奧地利進入日本市場的戰略合作夥伴，這些努力將在預測期內推動市場增長。

此外，越來越多的研究計劃旨在確定細胞封裝過程的臨床療效，這也推動了市場的增長。 越來越多的宣傳計劃與活細胞封裝在治療癌症和自身免疫性疾病等主要慢性疾病中的作用有關。 微膠囊可以解決的另一種疾病是 1 型糖尿病。 在這種疾病中，免疫系統會破壞胰腺中的 BETA 胰島細胞。 因此，我們封裝了產生胰島素的細胞，以防止它們被免疫系統破壞，同時允許封裝的細胞響應葡萄糖水平產生胰島素。 例如，根據 2022 年 5 月在 NGP Asia Material 上發表的題為通過微流體電噴霧技術生成的B細胞用於糖尿病治療的多孔微膠囊的研究，包裹活細胞的多孔微膠囊可以改善血糖水平，他的體重也有所改善。 這些特性表明包裹細胞的多孔微膠囊可有效治療糖尿病。因此，活細胞封裝療法在糖尿病治療中的功效被認為是促進市場增長的有前途的方法。

此外，全球糖尿病人口的增加也將支持預測期內的市場增長。 例如，根據國際糖尿病聯合會 2021 年 9 月的一份報告，到 2021 年，糖尿病將影響大約 5.37 億成年人（20-79 歲）。 到2030年，糖尿病患者總數預計將達到6.43億，到2045年將達到7.83億。 因此，越來越多的患者為市場參與者創造了重要的機會，為糖尿病患者的治療提供新型活細胞封裝藥物，這有望促進市場增長。

然而，優質原材料的高成本和替代療法的採用是製約市場增長的主要因素。

活細胞封裝市場趨勢

藥物輸送領域有望成為活細胞封裝市場的主要貢獻者

為了實現有效的藥物輸送，細胞包封用於製造片劑、膠囊和注射劑型。 由於其程序優勢（提高療效、降低毒性、提高患者依從性和便利性等），越來越多地在藥物輸送中使用細胞封裝促進了這一領域的增長。我來了。 細胞封裝用於製造有效的藥物輸送。

這種給藥方式的優勢在於其療效、耐受性和患者依從性。 例如，根據 2021 年 10 月發表的一項題為“用於藥物輸送的活性分子封裝方法”的研究，活細胞封裝可在特定組織部位或細胞中優先積累活性分子。同時提高藥物溶解度和滲透性，增加生物利用度，減少副作用，提高治療效果。 因此，活細胞封裝在藥物輸送中的優勢有望促進細分市場的增長。

此外，2020 年 12 月，Procyon Technologies LLC 與 Novo Nordisk A/S 就 Novo Nordisk 開髮用於開發 1 型糖尿病新型療法的植入式細胞封裝設備進行了獨家研究合作，並且我們簽署了許可協議。 預計這些努力將在預測期內推動該部門的增長。

微膠囊作為藥物輸送系統具有多種優勢。 它封裝活細胞以防止它們被免疫系統降解和破壞。 它精確地控制融合藥物在一段時間內（數小時至數月）的釋放速率，提供簡單的劑量和根據患者治療要求量身定制的預編程藥物釋放曲線。

因此，上述所有因素都有望在預測期內推動該細分市場的增長。

北美是活細胞封裝市場的主要收入地區之一

在整個預測期內，預計北美將主導整個活細胞封裝市場。 推動市場增長的因素包括主要參與者的存在、人均醫療保健支出的增加、美國和加拿大研發項目的資金和投資增加，以及完善的醫療保健基礎設施，所有這些都佔據了很大的市場份額。

根據美國研究與製藥製造商協會 (PhRMA) 2021 年 9 月的一份報告，生物製藥公司在過去十年中在研發方面的投資超過 1 萬億美元，其中 PhRMA 成員預計將在 2020 年加入。這創下了歷史記錄年，公司投資約 910 億美元。 因此，增加研發支出預計將為市場參與者創造重要機會，將技術先進的產品推向市場，推動該地區的市場增長。

此外，有利的政府舉措和新技術的傳播預計將推動該地區的市場增長。 例如，2021 年 11 月，Pharmacite Biotech，一家專注於使用該公司標誌性的活細胞封裝技術“盒中細胞”開發癌症和糖尿病細胞療法的生物技術公司，我們最近證實，所使用的空膠囊材料在我們的胰腺癌產品 CypCapsTM 中，不會刺激皮膚。 因此，預計主要市場參與者的此類舉措將在預測期內推動市場增長。

因此，上述所有因素都有望在預測期內提振市場。

活細胞封裝市場競爭者分析

根據研究範圍，活細胞封裝市場競爭相對激烈，由幾家大型企業組成。 目前的市場壟斷企業包括Viacyte, Inc、Living Cell Technologies Limited、Diatranz Otsuka Ltd、PharmaCyte Biotech Inc、Sernova Corporation、Sigilon Therapeutics, Inc、BUCHI Labortechnik AG、Blacktrace Holdings Ltd。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 擴大產品開發資金的公私投資
    • 增加研究以確定細胞封裝的臨床療效
    • 提高公眾對封裝細胞在疾病管理中作用的認識
  • 市場製約因素
    • 難以獲得優質原材料
    • 採用替代療法
  • 五力分析分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按製造技術
    • 簡單的點滴
    • 靜電滴
    • 同軸氣流
    • 轉盤霧化
    • 其他
  • 按聚合物類型
    • 藻酸鹽
    • 殼聚醣
    • 二氧化矽
    • 硫酸纖維素
    • 其他
  • 通過使用
    • 給藥
    • 再生醫學
    • 細胞移植
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Viacyte, Inc.
    • Living Cell Technologies Limited.
    • Diatranz Otsuka Ltd
    • PharmaCyte Biotech Inc
    • Sernova Corp
    • Sigilon Therapeutics, Inc.
    • Buchi Labortechnik AG
    • Blacktrace Holdings Ltd.
    • Atelerix Ltd.
    • Neurotech Pharmaceuticals, Inc
    • Kadimastem

第7章 市場機會與今後動向

簡介目錄
Product Code: 67507

The live-cell encapsulation market is expected to increase with a CAGR of nearly 3.2% during the forecast period, 2022-2027.

The Live-cell encapsulation market was significantly impacted by COVID-19. However, various COVID- 19 vaccines are RNA encapsulated. For instance, according to the study titled "COVID-19 Vaccine: A comprehensive status report" published in the Journal of Virus Research in October 2021, 1273 mRNA (Moderna TX, Inc) It's a vaccine made up of synthetic mRNA encapsulated in lipid nanoparticles (LNPs) that codes for SARS-full-length, CoV-2's pre-fusion stabilized spike protein. Additionally, Moderna and the Vaccine Research Centre are working on an mRNA-based vaccine candidate in which the mRNA is encapsulated in lipid nanoparticles, while Codagenix is working on a live attenuated viral vaccine in collaboration with the Serum Institute of India. Moreover, the Live cell Encapsules market is impacted by COVID-19.

The key factor accrediting to the growth of the live-cell encapsulation market is growing public-private investments to fund product development. For Instance, in July 2021, Austrianova, a global company with operations in Singapore and Thailand, is developing a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box) and bacterial (Bac-in-a-Box) cells using cellulose sulfate-based materials. Real Tech invested in a fund as a strategic partner for Austrianova's entry into the Japanese market as a result of this investment. such initiatives help to bolster the market growth over the forecast period.

Furthermore, the increasing research programs to establish the clinical efficacy of the cell encapsulation process are boosting the market growth. There are an increasing number of awareness programs related to the role of live cell encapsulation in the treatment of major chronic diseases like cancers, autoimmune diseases, etc. Another disorder microencapsulation can tackle is type 1 diabetes. In this condition, the beta islet cells of the pancreas are destroyed by the immune system. So the insulin-producing cells are encapsulated so that the immune system doesn't destroy them and, at the same time, let encapsulated cells respond to glucose levels by producing insulin. For instance, according to the study titled "Porous microcapsules encapsulating B cells generated by microfluidic electrospray technology for diabetes treatment" published in the NGP Asia Material in May 2022, with live cell porous microcapsules encasing cells, blood glucose levels and body weights improved as well. These characteristics suggest that porous microcapsules encasing cells are effective in the treatment of diabetes, and researchers believe that because of its superior capabilities, this method will be widely used in the clinic. As a result, the efficacy of live cell encapsulation therapy in the treatment of diabetes is a promising approach that is expected to boost market growth.

Moreover, the rising diabetes population across the world supports the market growth over the forecast period. For instance, as per the September 2021 report by the International Diabetes Federation, Diabetes affects approximately 537 million adults (20-79 years) in 2021. By 2030, the total number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million. Thus, rising in the number of cases creates a huge opportunity for the market player to bring the novel live cell encapsulated drug for the treatment of diabetics expected to boost the market growth.

However, the high cost of the good quality raw material and the adoption of alternative therapies as they are major factors restraining the growth of the market.

Live Cell Encapsulation Market Trends

Drug Delivery Segment is Expected to be the Major Contributor to the Live Cell Encapsulation market

For effective drug delivery, cell encapsulation is used in the production of tablets, capsules, and parenteral dosage forms. The increasing use of cell encapsulation for drug delivery is driving this segment's growth, owing to its procedural advantages (such as improved efficacy, reduced toxicity, and improved patient compliance & convenience). Cell encapsulation is used for the manufacturing of effective drug delivery.

The advantages of this type of drug delivery are its effectiveness, tolerability, and patient compliance. For instance, according to the study titled "Encapsulation methods of active molecules for drug delivery" published in October 2021, Live cell encapsulation improves drug solubility and permeability, improves bioavailability, reduces side effects, and improves therapeutic efficiency while providing preferential accumulation of active molecules at specific tissue sites or cells. Thus, the advantages of live-cell encapsulation in drug delivery are anticipated to boost the segment growth.

Additionally, in December 2020, Procyon Technologies LLC entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk's development of a novel therapy for Type 1 diabetes. Such initiatives are expected to bolster the segment growth over the forecast period.

Microencapsulation has various substantial advantages as a drug delivery system. They are encapsulated live cells against degradation or destruction by the immune system. It precisely controls the release rate of a fused drug over periods (hours to months), an easy administration, and pre-programmed drug-release profiles, which tally the therapeutic requirements of the patient.

Thus, all aforementioned factors are anticipated to boost the segment growth over the forecast period.

North America is One of the Major Income-Generating Regions in the Live Cell Encapsulation Market

North America is expected to dominate the overall live-cell encapsulation market throughout the forecast period. The market growth is due to factors such as the presence of key players, increasing per capita healthcare expenditure, increasing funding and investment for research and development programs in the United States and Canada, and established healthcare infrastructure are the key factors accountable for its large share in the market.

According to a report published in September 2021 by the Pharmaceutical Research and Manufacturers of America (PhRMA), in the last decade, biopharmaceutical companies invested more than a trillion dollars in research and development, including a record-breaking year in 2020 where PhRMA member companies invested about USD 91 billion in the research and development. Thus, increasing research and development spending creates a huge opportunity for the market players to bring the technologically advanced product into the market, which is anticipated to drive market growth in the region.

Furthermore, favorable government initiatives and the widespread adoption of new technology in the region are expected to boost market growth. For instance, in November 2021, PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, recently confirmed that the empty capsule material used in its CypCapsTM pancreatic cancer product does not irritate the skin. Thus, such initiatives by the key market players are anticipated to drive the growth of the market over the forecast period.

Thus, all aforementioned factors are anticipated to boost the market over the forecast period.

Live Cell Encapsulation Market Competitor Analysis

As per the scope of the report, the live-cell encapsulation market is relatively competitive and consists of several major players. Some of the companies which are currently dominating the market are Viacyte, Inc, Living Cell Technologies Limited., Diatranz Otsuka Ltd, PharmaCyte Biotech Inc., Sernova Corporation, Sigilon Therapeutics, Inc., BUCHI Labortechnik AG, Blacktrace Holdings Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Public-Private Investments to Fund Product Development
    • 4.2.2 Increasing Research to Establish the Clinical Efficacy of Cell Encapsulation
    • 4.2.3 Rising Public Awareness for Role of Encapsulated Cells in Disease Management
  • 4.3 Market Restraints
    • 4.3.1 Limited Availability of Good Quality Raw Material
    • 4.3.2 Adoption of Alternative Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Manufacturing Technique
    • 5.1.1 Simple Dripping
    • 5.1.2 Electrostatic Dripping
    • 5.1.3 Coaxial Airflow
    • 5.1.4 Rotating Disk Atomization
    • 5.1.5 Others
  • 5.2 By Polymer Type
    • 5.2.1 Alginate
    • 5.2.2 Chitosan
    • 5.2.3 Silica
    • 5.2.4 Cellulose Sulfate
    • 5.2.5 Others
  • 5.3 By Application
    • 5.3.1 Drug Delivery
    • 5.3.2 Regenerative Medicine
    • 5.3.3 Cell Transplantation
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Viacyte, Inc.
    • 6.1.2 Living Cell Technologies Limited.
    • 6.1.3 Diatranz Otsuka Ltd
    • 6.1.4 PharmaCyte Biotech Inc
    • 6.1.5 Sernova Corp
    • 6.1.6 Sigilon Therapeutics, Inc.
    • 6.1.7 Buchi Labortechnik AG
    • 6.1.8 Blacktrace Holdings Ltd.
    • 6.1.9 Atelerix Ltd.
    • 6.1.10 Neurotech Pharmaceuticals, Inc
    • 6.1.11 Kadimastem

7 MARKET OPPORTUNITIES AND FUTURE TRENDS